Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdomyosarcoma 1Neoplasms 1Myelodysplastic Syndromes 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Fanconi Anemia 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

fludarabine phosphate 6Antilymphocyte Serum 5fludarabine 4Cyclophosphamide 4Busulfan 4Peripheral Blood Stem Cell Transplantation 3Melphalan 3Filgrastim 3Cord Blood Stem Cell Transplantation 3thymoglobulin 2Radiotherapy 2Mycophenolic Acid 2Methylprednisolone 2Granulocyte Colony-Stimulating Factor 2sargramostim 1prexasertib 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Spectrometry, Fluorescence 1Reverse Transcriptase Polymerase Chain Reaction 1Quercetin 1Polymerase Chain Reaction 1Optical Imaging 1Molecular Diagnostic Techniques 1Microarray Analysis 1Immunoenzyme Techniques 1Ethanol 1Electrophoresis, Polyacrylamide Gel 1Dietary Supplements 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fanconi Anemia × prexasertib × Clear all
NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡